Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HK1 | P19367 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GALK1 | P51570 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridan SCHEMBL29446489 | 0.78 | MAPT (0.65) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL29405807 | 0.78 | MAPT (0.65) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL183367 | 0.78 | MAPT (0.65) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL20594012 | 0.78 | MAPT (0.65) | NPC1MAPTKDM4ERAB9AAHR | |
| SCHEMBL2087698 | 0.76 | TDP2 (0.66) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL15412652 | 0.75 | MAPT (0.62) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL10813635 | 0.75 | MAPT (0.62) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL29006126 | 0.75 | MAPT (0.62) | NPC1MAPTKDM4ERAB9AAHR | |
| SCHEMBL4571016 | 0.75 | MAPT (0.62) | NPC1MAPTKDM4ERAB9AAHR | |
| Acridan SCHEMBL28832553 | 0.75 | MAPT (0.62) | NPC1MAPTKDM4ERAB9AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021080997-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10927263-B2 | Polymerizable composition and optically anisotropic body produced using the same | DIC CORPORATION (JP) | 2021-02-23 | — | — | US | disclosed |
| US-20190264034-A1 | POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY PRODUCED USING THE SAME | DIC CORPORATION (JP) | 2019-08-29 | — | — | US | disclosed |
| WO-2017090418-A1 | POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY USING SAME | DIC株式会社 | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927263-B2 | Polymerizable composition and optically anisotropic body produced using the same | CRYAA, IK, LCP1 | NPC1 4720/4885MAPT 161/4885KDM4E 3187/4885 |
| US-20190264034-A1 | POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY PRODUCED USING THE SAME | CRYAA, IK, LCP1 | NPC1 4720/4885MAPT 161/4885KDM4E 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.